Pedro Cahn, MD, shares the results found after 96-weeks of follow-up for the onceMRK Phase 3 clinical trial.
Pedro Cahn, MD, Chief, Infectious Disease Unit, Juan A. Fernandez Hospital; and lead study investigator for the onceMRK Phase 3 clinical trial, shares the results found after 96-weeks of follow-up.
Interview Transcript (modified slightly for readability):
“The results of 96-weeks of follow-up for the onceMRK study were presented at the 9th IAS Conference on HIV Science in Paris. (The results of 48-weeks were presented at a prior conference.) What the study has shown is non-inferiority of the once-a-day formulation compared with the twice-a-day formulation.
[The study] was a well-powered, randomized clinical study in which patients were randomized 2:1. Meaning that, for each patient that was randomized to the classic twice-a-day formulation, those patients were classified to the once-a-day formulation. The results were extremely good, in the range of > 80% for both arms, without any surprises regarding tolerability.
Raltegravir once-a-day was well-tolerated as the twice-a-day formulation. We did not receive any complaints from the patients [in the trial], or notice issues with adherence. I think that all of the good [results] we had with raltegravir twice-a-day formulation, we now will see in a once-daily dosing, which is an obvious advantage and will help people adhere better to the treatments.”
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.